Compare Stocks

→ “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CBAY CymaBay Therapeutics	$32.48	$32.40	$7.26 ▼ $32.50	$3.73B	0.32	4.11 million shs	73 shs
CYDY CytoDyn	$0.15	$0.17	$0.13 ▼ $0.42	$144.96M	0.16	2.63 million shs	420,675 shs
NBSE NeuBase Therapeutics	$0.44 +4.7%	$0.68	$0.39 ▼ $4.80	$1.66M	0.83	202,576 shs	25,441 shs
OASM Oasmia Pharmaceutical AB (publ)	$0.02	$1.46	$0.94 ▼ $5.70	$1.50M	0.96	98,414 shs	N/A

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CBAY CymaBay Therapeutics	0.00%	0.00%	0.00%	+41.03%	+220.00%
CYDY CytoDyn	-1.68%	-3.22%	-11.52%	-9.46%	-48.48%
NBSE NeuBase Therapeutics	+4.99%	+4.15%	-7.69%	-29.90%	-82.87%
OASM Oasmia Pharmaceutical AB (publ)	0.00%	0.00%	0.00%	0.00%	-60.00%

“Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)

Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.

Find out why right here (and see what you can do to get in too with just a few dollars).

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CBAY CymaBay Therapeutics	1.0089 of 5 stars	2.0	0.0	0.0	4.7	0.0	2.5	0.6
CYDY CytoDyn	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NBSE NeuBase Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OASM Oasmia Pharmaceutical AB (publ)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CBAY CymaBay Therapeutics	2.08	Hold	$28.65	-11.79% Downside
CYDY CytoDyn	N/A	N/A	N/A	N/A
NBSE NeuBase Therapeutics	N/A	N/A	N/A	N/A
OASM Oasmia Pharmaceutical AB (publ)	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest CBAY, NBSE, OASM, and CYDY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
2/29/2024	CBAY CymaBay Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$32.50
2/20/2024	CBAY CymaBay Therapeutics	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$32.50
2/14/2024	CBAY CymaBay Therapeutics	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
2/14/2024	CBAY CymaBay Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral	$33.00 ➝ $32.50
2/14/2024	CBAY CymaBay Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$25.00 ➝ $32.50
2/13/2024	CBAY CymaBay Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
2/13/2024	CBAY CymaBay Therapeutics	Jonestrading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
2/13/2024	CBAY CymaBay Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$32.50
2/13/2024	CBAY CymaBay Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$29.00 ➝ $32.50
2/13/2024	CBAY CymaBay Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral

(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CBAY CymaBay Therapeutics	$31.07M	119.92	N/A	N/A	$2.58 per share	12.59
CYDY CytoDyn	$270K	536.89	N/A	N/A	($0.12) per share	-1.22
NBSE NeuBase Therapeutics	N/A	N/A	N/A	N/A	$11.04 per share	N/A
OASM Oasmia Pharmaceutical AB (publ)	$220K	6.82	N/A	N/A	$0.63 per share	0.03

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CBAY CymaBay Therapeutics	-$105.37M	-$0.97	N/A	N/A	N/A	N/A	-50.72%	-31.04%	5/20/2024 (Estimated)
CYDY CytoDyn	-$79.82M	-$0.05	N/A	∞	N/A	N/A	N/A	-478.47%	N/A
NBSE NeuBase Therapeutics	-$4.37M	-$7.70	N/A	∞	N/A	N/A	-99.74%	-60.13%	5/9/2024 (Estimated)
OASM Oasmia Pharmaceutical AB (publ)	-$18.95M	N/A	0.00	∞	N/A	-8,633.64%	-43.94%	-28.92%	N/A

Latest CBAY, NBSE, OASM, and CYDY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
4/15/2024	Q3 2024	CYDY CytoDyn	N/A	-$0.01	-$0.01	-$0.01	N/A	N/A
2/28/2024	Q4 2023	CBAY CymaBay Therapeutics	-$0.31	-$0.35	-$0.04	-$0.35	$0.42 million	$0.06 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CBAY CymaBay Therapeutics	N/A	N/A	N/A	N/A	N/A
CYDY CytoDyn	N/A	N/A	N/A	N/A	N/A
NBSE NeuBase Therapeutics	N/A	N/A	N/A	N/A	N/A
OASM Oasmia Pharmaceutical AB (publ)	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CBAY CymaBay Therapeutics	N/A	10.96	10.96
CYDY CytoDyn	N/A	0.08	0.08
NBSE NeuBase Therapeutics	N/A	2.87	2.87
OASM Oasmia Pharmaceutical AB (publ)	N/A	0.80	0.73

Ownership

Institutional Ownership

Company	Institutional Ownership
CBAY CymaBay Therapeutics	95.03%
CYDY CytoDyn	5.06%
NBSE NeuBase Therapeutics	12.37%
OASM Oasmia Pharmaceutical AB (publ)	0.11%

Insider Ownership

Company	Insider Ownership
CBAY CymaBay Therapeutics	7.00%
CYDY CytoDyn	0.71%
NBSE NeuBase Therapeutics	13.90%
OASM Oasmia Pharmaceutical AB (publ)	N/A

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CBAY CymaBay Therapeutics	101	114.72 million	106.69 million	Optionable
CYDY CytoDyn	12	992.87 million	985.82 million	Not Optionable
NBSE NeuBase Therapeutics	37	3.75 million	3.23 million	Not Optionable
OASM Oasmia Pharmaceutical AB (publ)	57	74.97 million	N/A	Not Optionable

CBAY, NBSE, OASM, and CYDY Headlines

Source	Headline
	Lipigon Pharmaceuticals AB LPGO morningstar.com - March 23 at 12:53 AM
	LSK BioPartners, Inc., Oasmia Pharmaceutical AB (publ) - Special Call Transcript gurufocus.com - March 6 at 9:00 AM
	Oasmia Pharmaceutical AB (publ) - Special Call Transcript gurufocus.com - March 6 at 9:00 AM
	Resurs Holding AB (publ) (RESURS.ST) finance.yahoo.com - February 8 at 12:32 AM
	QuiaPEG Pharmaceuticals Holding AB QUIA morningstar.com - January 6 at 5:30 PM
	Newbury Pharmaceuticals AB (NEWBRY) investing.com - November 29 at 2:08 AM
	Dentsu Creative bags mandate for Torrent Pharmaceuticals’ Shelcal & Unienzyme bestmediainfo.com - September 26 at 1:06 AM
	Lipigon Pharmaceuticals AB (LPGO) investing.com - September 14 at 9:09 AM
	Speqta publ AB (SPEQT) investing.com - August 25 at 9:50 PM
	PRXXF Paradox Interactive AB (publ) seekingalpha.com - August 25 at 9:29 AM
	Notice of annual general meeting in Alzinova AB (publ) privataaffarer.se - April 25 at 8:37 AM
	Report from Annual General Meeting 2023 of PowerCell Sweden AB (publ) privataaffarer.se - April 21 at 8:26 PM
	Notice of Annual General Meeting 2023 in Enzymatica AB (publ) (2) europapress.es - April 2 at 9:53 AM
	OXE Marine AB (publ) Non-GAAP EPS of -SEK0.43, revenue of SEK32.2M seekingalpha.com - February 26 at 11:56 PM
	US regulators clear way for more monkeypox vaccine shipments starherald.com - July 14 at 11:12 AM
	PRELIMINARY RESULT OF OASMIA’S RIGHTS ISSUE (MFN) avanza.se - March 24 at 6:47 AM
	Oasmia expands R&D ability with planned laboratory upgrade privataaffarer.se - March 17 at 8:40 AM
	Orexo appoints Fredrik Järrsten as new CFO stockhouse.com - March 11 at 3:47 AM
	Notice of extra general meeting in Terranet AB finanznachrichten.de - November 29 at 10:24 AM
	Pet Cancer Therapeutics Market – Know-How Industry to Experience Positive Growth \| robust CAGR of 7.7% over the forecast period (2017 – 2025). medgadget.com - September 17 at 2:52 AM
	Veterinary Cancer Therapeutics Market Segmentation, Size Analysis, Key Players Forecast To 2027 openpr.com - July 28 at 7:04 PM
	Fancy Wood Industries PCL (FANCY) investing.com - July 22 at 7:07 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

CymaBay Therapeutics

NASDAQ:CBAY

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California.

CytoDyn

OTCMKTS:CYDY

CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

NeuBase Therapeutics

NASDAQ:NBSE

NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.

Oasmia Pharmaceutical AB (publ)

NASDAQ:OASM

Oasmia Pharmaceutical AB engages in the research and development of drugs. It formulates pharmaceutical products for ovarian and breast cancer for humans and cancer for animals. The company was founded by Julian Aleksov and Bo Cederstrand on April 15, 1988 and is headquartered in Uppsala, Sweden.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial